Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43474 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL203118 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL2639323 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL202447 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL12775011 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107453 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL23765660 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107454 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL454356 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL13079441 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605121-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | Encapsys, LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119317482-A | Delivery particles based on amine-thiol-ene conjugates and derivatives | 恩盖普有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024086501-A9 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | ENCAPSYS, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024086501-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | ENCAPSYS, LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | THE UNIVERSITY OF KANSAS (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022036101-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| WO-2018134731-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134731-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-26 | — | — | WO | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | MEN1 3820/4885KMT2A 408/4885ODC1 3550/4885 |
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | EXOSC10, ADAM10, HCCS | MEN1 830/4885KMT2A 1296/4885ODC1 4065/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | MEN1 3665/4885KMT2A 3572/4885ODC1 4824/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | MEN1 3278/4885KMT2A 3699/4885ODC1 4828/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | MEN1 4092/4885KMT2A 3976/4885ODC1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.